MedTrace Logo

Ozonated Gel and Titanium Platelet-rich Fibrin (on Palatal Wound Healing

NCT07320391 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2026-01-06

No results posted yet for this study

Summary

Background: autogenous soft tissue grafts can be considered the gold standard for treatment of mucogingival problems. The most common site for harvesting the graft is the palate. The palatal donor site for free gingival graft (FGG) significantly influences the pain and discomfort experienced by the patient, and there is a potential for postoperative bleeding.To overcome these problems many dressing materials associated with topical formulae have been used.

Aim: The objective of this study is to assess the effect of topically applied ozonated oil on palatal wound healing and compare it to the effect of titanium platelet rich fibrin (TPRF)

Conditions

  • Palatal Lesion

Interventions

OTHER

Ozonated Gel Application

After harvesting the free palatal grafts, an adrenaline-soaked sterile surgical gauze was applied to the palatal donor sites with firm pressure for 5 minutes to achieve hemostasis. Subsequently, ozonated gel loaded on gelatin foam was placed over the donor sites and stabilized using flowable composite.

OTHER

T-PRF Application

Twenty milliliters of venous blood were collected from the antecubital vein and immediately centrifuged at 2800 rpm for 12 minutes. The resulting T-PRF clots were retrieved using sterile tweezers, separated from the red blood cell layer, and placed on sterile woven gauze. The clots were allowed to exude serum for 20 minutes, then gently compressed between gauze to form T-PRF membranes. The membranes were trimmed to fit the FGG donor site and covered with flowable composite.

OTHER

Conventional treatment

After harvesting the free palatal grafts, an adrenaline-soaked sterile surgical gauze was applied to the palatal wounds with firm pressure for 5 minutes to achieve hemostasis. The palatal wounds were then covered with flowable composite.

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-05-30
Completion
2025-05-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07320391 on ClinicalTrials.gov